Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy
Data Collection
Anemia
+ Hematologic Diseases
Treatment Study
Summary
Study start date: February 1, 2004
Actual date on which the first participant was enrolled.The purpose of this study is to examine the effectiveness of epoetin alfa in treating anemia in patients who have cancer or who no longer have any signs of the cancer, but remain anemic as a result of their treatment.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria: * 18 years of age or older * Body weight \>/= 99lbs * ECOG 0-2 * Anemia results from cancer, chemotherapy, radiotherapy or an association with hormonal therapy or immunotherapy * Screening hemoglobin level of \</= 11.0 g/dL for men or \</= 10.0 for women Exclusion Criteria: * History of or concurrent second malignancy * Evidence of primary or metastatic malignancy involving the Central Nervous System
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 6 locations
Shapiro, Stafford & Yee
Arcadia, United StatesCalifornia Cancer Center
Fresno, United StatesTukoi Research
North Miami, United States